By Josh White
Date: Wednesday 20 Dec 2023
LONDON (ShareCast) - (Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive has received its first orders for Genedrive MT-RNR1 products from several countries, it announced on Wednesday, including France, Austria, Greece, Saudi Arabia, Turkey, and the Netherlands.
The AIM-traded firm said the orders came in the wake of its recent confirmation of commercial distribution agreements for the Genedrive test for antibiotic-induced hearing loss (AIHL) in multiple nations.
It said the initial orders were intended to support its international distribution partners in their efforts to promote and evaluate the product within their respective countries.
"We are delighted to see the first orders come in from those countries we have signed distribution agreements with," said chief executive officer James Cheek.
"We look forward to the continued expansion of our international sales throughout 2024 as we drive forward with our sales and marketing strategies and deliver value to our shareholders."
At 1331 GMT, shares in Genedrive were up 24.37% at 9.95p.
Reporting by Josh White for Sharecast.com.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 2.45p |
Change Today | 0.050p |
% Change | 2.08 % |
52 Week High | 9.50 |
52 Week Low | 1.45 |
Volume | 18,419,832 |
Shares Issued | 543.14m |
Market Cap | £13.31m |
Beta | 1.12 |
RiskGrade | 747 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
15:19 | 3,000,000 @ 2.50p |
16:28 | 50,000 @ 2.40p |
16:18 | 9,828 @ 2.41p |
16:17 | 83,160 @ 2.41p |
16:06 | 7,000 @ 2.41p |
You are here: research